General description
Poly(oligo(ethylene glycol) methacrylate) (POEGMA) is a family of polymers consisting of a hydrophobic methacrylate backbone and hydrophilic ethylene oxide (EO) side groups with highly branched architecture. The highly branched architecture with a high density of oligo EO moities enhances the solubility of the polymer in water.
Application
Poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA) is a family of polymers consisting of a hydrophobic methacrylate backbone and hydrophilic ethylene oxide (EO) side groups with highly branched architecture . The side chain EO segments enhance the solubility of the polymer in water , exhibiting many interesting properties such as non-fouling , stealth, anti-PEG antibodies & thermo-responsive behaviors.
- Drug delivery- enhances the stability and delivery of siRNA and eliminates PEG antigenicity
- Biosensor coatings- provides an anti-fouling surface
- Stimuli-responsive hydrogels for tissue engineering, drug delivery, and other biomedical applications
Features and Benefits
- Highly branched architecture and high density of oligo ethylene oxide moieties
- Water soluble
- Nonfouling and thermo-responsive behaviors
- Viable alternative to PEG in biological and biomaterial applications
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Rafael Pires-Oliveira et al.
Langmuir : the ACS journal of surfaces and colloids, 36(49), 15018-15029 (2020-12-05)
Understanding of the temperature-induced phase transition of poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA) random copolymers with varied composition remains largely incomplete. Upon heating they can form either macroscopically phase-separated aggregates or micelles. We examined the effect of polymer architecture by
In Pursuit of Zero 2.0: Recent Developments in Nonfouling Polymer Brushes for Immunoassays
Heggestad J., et al.
Advanced Materials, 32 (2020)
Yizhi Qi et al.
Nature biomedical engineering, 1 (2016-01-01)
The delivery of therapeutic peptides and proteins is often challenged by a short half-life, and thus the need for frequent injections that limit efficacy, reduce patient compliance and increase treatment cost. Here, we demonstrate that a single subcutaneous injection of
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 930741-1G | 04065268917312 |